Just the Facts on ZIOPHARM Oncology, Inc. (ZIOP)

ZIOPHARM Oncology, Inc. (ZIOP) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $4.51, up from yesterday’s close by 4.40%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

ZIOPHARM Oncology, Inc. (ZIOP) currently trades with a market capitalization of $644.66 Million. That value represents a market adjusting for revenues that have been growing by 0.00 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of -$55.41 Million over the past twelve months. Generally speaking, earnings are expected to hold steady in coming quarters. Analysts are forecasting earnings of -$0.13 on a per share basis this quarter. Perhaps, that suggests something about why 3.48% of the outstanding share supply is held by institutional investors.

Technical Analysis

We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, ZIOPHARM Oncology, Inc. recorded a 52-week high of $7.88. It is now trading 3.37% off that level. The stock is trading $4.06 its 50-day moving average by -0.45%. The stock carved out a 52-week low down at $3.33.

In recent action, ZIOPHARM Oncology, Inc. (ZIOP) has made a move of +1.58% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 14.08, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 25.42% with $139.17 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ZIOP.

Previous articleThe Case for and Against Clovis Oncology, Inc. (CLVS)
Next articleTaking a Look at the Data Behind Sunrun Inc. (RUN)